TOPFUND WHERE YOUR MONEY GROWS
Home / Stocks / Nephrocare Health Serv L
NEPHROPLUS

Nephrocare Health Serv L Share Price

Live price, chart and which mutual funds hold this stock

TopFund Score: 68/100 · Good See breakdown ↓
…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 25 Sep 2026

₹696.65

Change

-12.85 (-1.81%)

Open

₹715.0

Prev. Close

₹709.5

Day High

₹719.0

Day Low

₹693.7

Volume Analysis

Traded

592,871

Delivered

454,580

Delivery %

76.67%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Strong operating margin (22.0%)

Weaknesses (1)

  • •Low return on equity (8.83%)

Opportunities (1)

  • •Strong 3-year revenue growth (31.7%)

Threats (1)

  • •FII holding has been falling

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹737.84 ₹728.42 ₹712.54 ₹703.12 ₹687.24 ₹677.82 ₹661.94
Fibonacci ₹728.42 ₹718.76 ₹712.78 ₹703.12 ₹693.46 ₹687.48 ₹677.82
Camarilla ₹703.61 ₹701.29 ₹698.97 ₹703.12 ₹694.33 ₹692.01 ₹689.69

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+52.84%

1 Week

-7.31%

1 Month

+0.62%

3 Months

+2.85%

6 Months

+31.87%

1 Year

—

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹138.31

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

7.19%

Net margin 8.07% × asset turnover 0.68x × equity multiplier 1.31x

Company Overview

Sector

Healthcare

Market Cap

₹7,005 Cr

P/E (TTM)

82.3

ROE

8.83%

Book Value

₹111.0

Face Value

₹2.0

Source: Screener.in (Consolidated figures) — data as of 26 Sep 2026. Not investment advice.

TopFund Analysis

Nephrocare Health Serv L holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 68/100. The strongest factor is Financial Strength (100/100), while Valuation (10/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (22.0%); low return on equity (8.83%). FII holding has been falling.

TopFund Score — Fundamentals Quality

68/100 — Good

Data confidence: 78/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 27 Sep 2026 · How we calculate this →

Financial Strength

100

Growth

96

Valuation

10

Cash Flow

67

Corporate Governance

56

Momentum

75

Institutional Ownership

43

Business Quality

64

Risk & Volatility

70

Liquidity

100

From Screener.in

  • +Company has reduced debt.
  • +Company is almost debt free.
  • +Company has delivered good profit growth of 162% CAGR over last 5 years
  • −Stock is trading at 6.26 times its book value
  • −Though the company is reporting repeated profits, it is not paying out dividend
  • −Company has a low return on equity of 10.2% over last 3 years.
  • −Company's cost of borrowing seems high

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Closure of Trading Window 25 Sep

Trading window closes from October 1, 2026 until 48 hours after Q2/H1 FY26 results.

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 22 Sep

Company to attend PL Capital investor conference on September 29, 2026 in Mumbai.

Announcement under Regulation 30 (LODR)-Credit Rating 18 Sep

India Ratings upgrades bank loan facilities to IND AA-/Stable and affirms short-term IND A1+ on Sept. 18, 2026.

Announcement under Regulation 30 (LODR)-Restructuring 18 Sep

Board approved consolidation of Philippines step-down subsidiaries on September 18, 2026.

Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements 14 Sep

Nephrocare subsidiary agreed to buy dialysis center assets in Philippines for PhP 67.2 million (₹10.25 crore) on Sept. 14, 2026.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Sales + 197 219 228 246 260 266 282
Expenses + 153 168 180 182 199 215 221
Operating Profit 44 51 48 64 61 51 60
OPM % 22.0% 23.0% 21.0% 26.0% 23.0% 19.0% 21.0%
Other Income + 5 4 7 4 3 12 7
Interest 5 6 6 45 6 3 2
Depreciation 18 19 20 23 22 26 25
Profit before tax 26 30 29 -1 36 33 41
Tax % 24.0% 17.0% 17.0% 1,427.0% 11.0% 9.0% 22.0%
Net Profit + 20 25 24 -9 32 30 32
EPS in Rs 97 119 13 -5 3 3 3
Raw PDF — — — — — — —

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 286 318 437 566 756 999 1,053
Expenses + 248 302 389 465 589 774 817
Operating Profit 37 16 49 101 167 225 236
OPM % 13.0% 5.0% 11.0% 18.0% 22.0% 23.0% 22.0%
Other Income + 5 10 6 8 14 23 26
Interest 7 10 16 20 21 60 56
Depreciation 34 42 47 56 72 91 96
Profit before tax 1 -27 -9 33 87 97 110
Tax % 31.0% -21.0% 37.0% -6.0% 23.0% 21.0% —
Net Profit + 1 -21 -12 35 67 77 85
EPS in Rs 3 -107 -59 170 322 8 4
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% —

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Reserves 245 391 384 409 579 1,096
Borrowings + 140 119 200 271 261 80
Other Liabilities + 42 59 81 124 153 271
Total Liabilities 428 571 666 806 994 1,467
Fixed Assets + 192 205 239 356 396 517
CWIP 2 43 34 1 6 6
Investments 0 0 0 0 51 178
Other Assets + 234 322 393 449 542 767
Total Assets 428 571 666 806 994 1,467
Equity Capital 2 2 2 2 2 20

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 32 14 11 72 135 233
Cash from Investing Activity + -62 -130 -76 -52 -125 -392
Cash from Financing Activity + 36 121 60 27 54 157
Net Cash Flow 5 6 -4 47 65 -2
CFO/OP 49 119 14 80 82 116
Free Cash Flow -29 -64 -62 -8 35 113

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 63.85% → 63.85%
  Dec 2025 Mar 2026 Jun 2026
Public 18.74% 17.56% 18.3%
Promoters 63.85% 63.85% 63.85%
FII 9.3% 9.94% 8.78%
DII 8.1% 8.64% 9.05%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Nephrocare Health Serv L (this stock) 7,005 82.3 6.28 8.83%
Sun Pharma Adv.res.co.ltd 6,784 4.25 5.06 279.0%
Sanofi India Limited 7,232 16.4 8.4 47.1%
Kovai Medical Center & Ho 6,653 115.0 23.07 22.2%
Innova Captab Limited 7,402 48.1 6.78 13.7%
Morepen Lab. Ltd 6,596 56.2 5.26 5.33%
Bliss Gvs Pharma Ltd 7,486 54.4 6.23 11.8%

Which Mutual Funds Hold Nephrocare Health Serv L?

Frequently Asked Questions about Nephrocare Health Serv L

Community Sentiment

What are other investors saying about Nephrocare Health Serv L?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.